Joseph Baur to present at the 8th Aging Research & Drug Discovery Meeting 2021


Tuesday, June 15, 2021 — Joseph A. Baur, PhD., will present the latest research on the topic SLC25A51 controls mitochondrial NAD levels at the worlds’ largest annual

Aging Research and Drug Discovery conference (8th ARDD)

. Dr. Joseph Baur is the Associate Professor of Physiology at the University of Pennsylvania.

Joseph Baur earned his Ph.D. from the University of Texas Southwestern Medical Center in Dallas, Texas, where he studied mechanisms that limit the lifespan of cultured human cells under Drs. Jerry Shay and Woody Wright. He then moved to Harvard Medical School where he trained as a postdoctoral fellow with Dr. David Sinclair. There he developed a strong interest in the regulation of aging and metabolism by sirtuins, a conserved class of enzymes that require nicotinamide adenine dinucleotide (NAD) as a co-substrate. His lab currently studies metabolic and signaling pathways by which nutrient intake can influence longevity, with a particular emphasis on NAD and mTOR.

“Nicotinamide adenine dinucleotide is essential for mitochondrial function, but how this cofactor gets inside the organelles has not been known. Recently, we and others identified SLC25A51 as a mitochondrial transporter that is essential for importing NAD to support mitochondrial respiration.” said Joseph A.Baur, PhD, Associate Professor at the University of Pennsylvania.

The conference proceedings of the ARDD are commonly published in peer-reviewed journals with the talks openly available at

http://www.

agingpharma.

org

. Please review the conference proceedings for 2019 and 2020.

“Aging is emerging as a druggable condition with multiple pharmaceuticals able to alter the pace of aging in model organisms. The ARDD brings together all levels of the field to discuss the most pressing obstacles in our attempt to find efficacious interventions and molecules to target aging. The 2021 conference is the best yet with top level speakers from around the globe. I’m extremely excited to be able to meet them in person at the University of Copenhagen in late summer.”, said Morten Scheibye-Knudsen, MD, Ph.D., University of Copenhagen.

“Aging research is growing faster than ever on both academia and industry fronts. The ARDD meeting unites experts from different fields and backgrounds, sharing with us their latest groundbreaking research and developments. Our last ARDD meeting took place online and was a great success. This year’s event will be a hybrid meeting with virtual and in-person attendees. I am particularly excited that being part of the ARDD 2021 meeting will provide an amazing opportunity for young scientists presenting their own work as well as meeting the experts in the field.” said Daniela Bakula, Ph.D., University of Copenhagen

“Aging research is gaining traction in the biopharmaceutical industry. To my knowledge, 6 out of the top 30 pharmaceutical companies in the world prioritized aging research for early-stage discovery or therapeutic pipeline development and several companies employ artificial intelligence for this purpose. We organize the annual ARDD conference for eight years in a row and the level of interest in aging biomarkers and noticed exponential growth in registrations over the past two years”, said Alex Zhavoronkov, Ph.D., co-founder and CEO of Insilico Medicine, and the founder of Deep Longevity.

Building on the success of the ARDD conferences, the organizers developed the “Longevity Medicine” course series with some of the courses offered free of charge at

Longevity.Degree

covered in the recent Lanced Healthy Longevity paper titled “Longevity medicine: upskilling the physicians of tomorrow”.

###


About Aging Research for Drug Discovery Conference

At ARDD, leaders in the aging, longevity, and drug discovery field will describe the latest progress in the molecular, cellular and organismal basis of aging and the search for interventions. Furthermore, the meeting will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. Notably, this year we are expanding with a workshop specifically for physicians where the leading-edge knowledge of clinical interventions for healthy longevity will be described. ARRD intends to bridge clinical, academic and commercial research and foster collaborations that will result in practical solutions to one of humanity’s most challenging problems: aging. Our quest? To extend the healthy lifespan of everyone on the planet.


About Scheibye-Knudsen Lab

In the Scheibye-Knudsen lab we use in silico, in vitro and in vivo models to understand the cellular and organismal consequences of DNA damage with the aim of developing interventions. We have discovered that DNA damage leads to changes in certain metabolites and that replenishment of these molecules may alter the rate of aging in model organisms. These findings suggest that normal aging and age-associated diseases may be malleable to similar interventions. The hope is to develop interventions that will allow everyone to live healthier, happier and more productive lives.


About Deep Longevity

Deep Longevity has been acquired by Regent Pacific (SEHK:0575.HK), whose shares are listed on the Hong Kong Stock Exchange. Deep Longevity is developing explainable artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. It is also developing systems for the emerging field of longevity medicine enabling physicians to make better decisions on the interventions that may slow down, or reverse the aging processes. Deep Longevity developed Longevity as a Service (LaaS)© solution to integrate multiple deep biomarkers of aging dubbed “deep aging clocks” to provide a universal multifactorial measure of human biological age. Originally incubated by Insilico Medicine, Deep Longevity started its independent journey in 2020 after securing a round of funding from the most credible venture capitalists specializing in biotechnology, longevity, and artificial intelligence. ETP Ventures, Human Longevity and Performance Impact Venture Fund, BOLD Capital Partners, Longevity Vision Fund, LongeVC, co-founder of Oculus, Michael Antonov, and other expert AI and biotechnology investors supported the company. Deep Longevity established a research partnership with one of the most prominent longevity organizations, Human Longevity, Inc. to provide a range of aging clocks to the network of advanced physicians and researchers.

https:/

/

deeplongevity.

com/


About Regent Pacific (SEHK:0575.HK)

Regent Pacific is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare, wellness and life sciences sectors. The Group has a strong track record of investments and has returned approximately US$298 million to shareholders in the 21 years of financial reporting since its initial public offering.

https:/

/

www.

regentpac.

com/

This part of information is sourced from https://www.eurekalert.org/pub_releases/2021-06/dll-jbt061421.php

withyou android app